drugset
drugset / Trial / NCT04982991

Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants

NCT04982991 ↗

Phase 1 Completed 14 enrolled Sanofi
NaCrossoverOpen-labelTreatment

Summary

Primary Objective: To assess the pharmacokinetic parameters of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants. Secondary Objective: To assess the tolerability and safety of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants

Timeline

Start
2021-08-05
Primary completion
2021-10-11
Completion
2021-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ODITRASERTIB Small molecule — Oral

Indications

No indication recorded.